Shanghai MicuRx Pharmaceutical Co., Ltd. Class A

As of June 30, 2026, Shanghai MicuRx Pharmaceutical Co., Ltd. Class A carries a market capitalization of 2.97B, placing it among publicly traded companies globally. Its enterprise value stands at 2.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai MicuRx Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Shanghai MicuRx Pharmaceutical Co., Ltd. Class A has 656.23M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 18.86, and the price-to-book ratio stands at 18.24.

These figures are as of June 30, 2026. The EV/Sales ratio of 18.25 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.94B versus a market cap of 2.97B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Shanghai MicuRx Pharmaceutical Co., Ltd. Class A maintains a current ratio of 2.18, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 221.36, indicating elevated leverage, while an interest coverage ratio of -13.30 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Shanghai MicuRx Pharmaceutical Co., Ltd. Class A posted a negative return on equity (ROE) of -59.45, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -21.97, reflecting losses generated across the asset base. The company generates approximately 939,185.11 in revenue per employee across its workforce of 171.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.47 indicates how many times Shanghai MicuRx Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shanghai MicuRx Pharmaceutical Co., Ltd. Class A recorded an income tax benefit of -6.68M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -169.25M and -162.68M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Shanghai MicuRx Pharmaceutical Co., Ltd. Class A's stock has declined approximately 36.66% over the past 52 weeks. The 50-day moving average sits at 5.47, while the 200-day moving average is 5.60.

Over the twelve months ended June 30, 2026, Shanghai MicuRx Pharmaceutical Co., Ltd. Class A generated 161.07M in revenue and converted that into -162.68M in net income, yielding earnings per share of -0.24. EBITDA reached -168.78M, while operating income came in at -166.00M.

As of June 30, 2026, Shanghai MicuRx Pharmaceutical Co., Ltd. Class A holds 393.58M in cash and equivalents against 360.70M in total debt, resulting in a net debt position of -110.39M. Total book value stands at 162.95M, with working capital of 296.85M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai MicuRx Pharmaceutical Co., Ltd. Class A posted a gross margin of 85.81, reflecting its pricing power and cost economics. The operating margin of -103.06 and net profit margin of -101.00 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Shanghai MicuRx Pharmaceutical Co., Ltd. Class A paid dividends of 0.01 per share. The dividend payout ratio of -5.71 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.82, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shanghai MicuRx Pharmaceutical Co., Ltd. Class A shareholders.

As of June 30, 2026, Shanghai MicuRx Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of -0.86, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.